Press release content from Globe Newswire. The AP news staff was not involved in its creation.
GT Gain Therapeutics SA Announces Funding from the Swiss Innovation Agency Supporting a 3-year .
Gain TherapeuticsDecember 15, 2020 GMT
- Researchers will further develop the Site-directed Enzyme Enhancement Therapy (SEE-Tx) ™
technology for the treatment of rare genetic and neurodegenerative diseases
- The collaborative agreement unites resources from the Institute for Research in Biomedicine (IRB)-USI;
Neurocentro - Ente Ospedaliero Cantonale (EOC) & GT GAIN Therapeutics, SA
LUGANO, Switzerland, Dec. 15, 2020 (GLOBE NEWSWIRE) GT Gain Therapeutics SA (“Gain”), a subsidiary of Gain Therapeutics, Inc., a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites that have never before been targeted, along with the Institute for Research in Biomedicine (IRB, affiliated to USI Università della Svizzera Italiana) and the
GT Gain Therapeutics SA Announces Funding from the Swiss Innovation Agency Supporting a 3-year Research Collaboration Project with the Institute for Research in Biomedicine and Neurocentro
technology for the treatment of rare genetic and neurodegenerative diseases
- The collaborative agreement unites resources from the Institute for Research in Biomedicine (IRB)-USI;
Neurocentro - Ente Ospedaliero Cantonale (EOC) & GT GAIN Therapeutics, SA
LUGANO, Switzerland, Dec. 15, 2020 (GLOBE NEWSWIRE) GT Gain Therapeutics SA ( Gain ), a subsidiary of Gain Therapeutics, Inc., a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites that have never before been targeted, along with the Institute for Research in Biomedicine (IRB, affiliated to USI Università della Svizzera Italiana) and the Neurocentro announced today that Innosuisse, the Swiss Innovation Agency, has agreed to support the CHF 1.5M project by funding approximately